Inhibition of human interleukin-12 production by pentoxifylline

Immunology

Volumn 91, Issue 2, 1997, Pages 197-203

  Moller, D R ^a,e   Wysocka, M ^c   Greenlee, B M ^a   Ma, X ^c   Wahl, L ^d   Trinchieri, G ^c   Karp, C L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WISTAR INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; REGULATORY MECHANISM;

EID: 0030984962     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1997.00246.x     Document Type: Article

References (45)

1. TRINCHIERI G. (1995) Inerleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13, 251.
2. LOCKSLEY R.M. (1993) Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 90, 5879.
3. TREMBLEAU S., GERMANN T., GATELY M.K. & ADORINI L. (1995) The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16, 363.
4. LEONARD J.P., WALDBURGER K.E. & GOLDMAN S.J. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 181, 381.
5. GERMANN T., SZELIGA J., HESS H. et al. (1995) Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 92, 4823.
6. NEURATH M.F., FUSS I., KEISALL B.L., STUBER E. & STROBER W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182, 1281.
7. WILLIAMSON E., GARSIDE P., BRADLEY J.A. & MOWAT A.M. (1996) IL-12 is a central mediator of acute graph-vs.-host disease in mice. J Immunol 157, 689.
8. SEDER R.A., KELSALL B.L. & JANKOVIC D. (1996) Differential roles for IL-12 in the maintenance of immune responses in infectious vs. autoimmune disease. J Immunol 157, 2745.
9. MOLLER D.R., FORMAN J.D., LIU M.C. et al. (1996) Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 156, 4952.
10. WARD A. & CLISSOLD S.P. (1987) Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34, 50.
11. SCHWARZ A., KRONE C., TRAUTINGER F. et al. (1993) Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 101, 549.
12. MAKSYMOWYCH W.P., AVINA-ZUBIETA A., LUONG M.H. & RUSSELL A.S. (1995) An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. 22, 625.
13. RIECKMANN P., WEBER F., GUNTHER A. et al. (1995) Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64, 193.
14. STRIETER R.M., REMICK D.G., WARD P.A. et al. (1988) Cellular and molecular regulation of tumor necrosis factor - alpha production by pentoxifylline. Biochem Biophys Res Commun 155, 1230.
15. ZABEL P., WOLTER D.T., SCHONHARTING M.M. & SCHADE F.U. (1989) Oxpentifylline in endotoxaemia. Lancet 334, 1474.
16. LECHNER A.J., ROUBEN L.R., POTTHOFF L.H., TREDWAY T.L. & MATUSCHAK G.M. (1993) Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ Shock 39, 306.
17. TILG H., EIBL B., PICHL M. et al. (1993) Immune response modulation by pentoxifylline in vitro. Transplantation 56, 196.
18. ROTT O., CASH E. & FLEISCHER B. (1993) Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23, 1745.
19. THANHAUSER A., REILING N., BOHLE A. et al. (1993) Pentoxifylline: a potent inhibitor of IL-2 and IFNγ-biosynthesis and BCG-induced cytotoxicity. Immunology 80, 151.
20. ZABEL P., SCHADE F.U. & SCHLAAK M. (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiol 187, 447.
21. HAN J., THOMPSON P. & BEUTLER B. (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172, 391.
22. FORMAN J.D., KLEIN J.T., SILVER R.F., LIU M.C., GREENLEE B.M. & MOLLER D.R. (1994) Selective activation and accumulation of oligoclonal Vβ-specific T cells in active pulmonary sarcoidosis. J Clin Invest 94, 1533.
23. WAHL L.M., KATONIA I.M., WILDER R.L. et al. (1984) Isolation of human mononucleur cell subsets by counterflow centrifugal elutriation (CCE). Cell Immunol 85, 373.
24. D'ANDREA A.D., RENGARAJU M., VALIANTE N.M. et al. (1992) Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 176, 1387.
25. WAHL, L.M. (1981) Production and quantitation of prostaglandins. In: Manual of Macrophage Methodology (eds H. B. Herscowitz, H. T. Holden, J. A. Bellanti & A. Ghaffar), p. 432. Marcel Dekker Inc., New York and Basel.
26. CHOMCZYNSKI P. & SACCHI N. (1987) Single-step method of RNA isolation by acid quanidinium thiocyanate phenol chloroform extraction. Anal Biochem 162, 156.
27. D'ANDREA A.M., MA X., ASTE-AMEZAGE M., PAGANIN C. & TRINCHIERI G. (1995) Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J Exp Med 181, 537.
28. MA X., CHOW J.M., GRI G. et al. (1996) The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J Exp Med 183, 147.
29. VAN DER POUW KRAAN T.C.T.M., BOEIJE L.C.M., SMEENK R.J.T., WIJDENES J. & AARDEN L.A. (1995) Prostaglandin-E2 is a potent inhibitor of human interleukin-12 production. J Exp Med 181, 775.
30. REED W.R. & DEGOWIN R.L. (1992) Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 119, 763.
31. KAMMER G.M. (1988) The adenylate cyclase-cAMP-proteinkinase: a pathway and regulation of the immune response. Immunol Today 9, 222.
32. MURPHY T.L., CLEVELAND M.G., KULESZA D., MAGRAM J. & MURPHY K.M. (1995) Regulation of interleukin-12 p40 expression through an NF-kappaB half-site. Molec Cell Biol 15, 5258.
33. BISWAS D.K., DEZUBE B.J., AHLERS C.M. & PARDEE A.B. (1993) Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kB action. J Acquired Immune Deficiency Syndromes 6, 778.
34. NAVARRO J., PUNZON M.C., PIZARRO A., FERNANDEX-CRUZ E., FRESNO M. & MUNOZ-FERNANDEX M.A.M. (1996) Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumor necrosis factor synthesis or nuclear factor-kB activation. AIDS 10, 469.
35. BERTAGNOLLI M.M., LIN B.-Y., YOUNG D. & HERRMANN S.H. (1992) IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol 149, 3778.
36. PERUSSIA B., CHAN S.H., D'ANDREA A. et al. (1992) Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ +, TCR-γδ + T lymphocytes, and NK cells. J Immunol 149, 3495.
37. BESSLER H., GILBAL R., ZAHAVI I. & DJALDETTI M. (1987) Effect of pentoxifylline on E-rosette formation and on the mitogenic response of mononuclear cells. Biomed Pharmacother 41, 439.
38. SINGER J.W., BIANCO J.A., TAKAHASHI G., SIMRELL C., PETERSON J. & ANDREWS D.F. (1991) Effect of methylxanthine derivatives on T cell activation. Bone Marrow Transplan 10, 18.
39. MCEVOY G.K. (1996) AHFS Drug Information. American Society of Health-System Pharmacists Inc., Bethesda, MD, USA.
40. DEZUBC B.J., EDER J.P. & PARDEE A.B. (1990) Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Res 50, 6806.
41. CHEHIMI J., STARR S., FRANK I. et al. (1994) Impaired interleukin-12 production in human immunodeficiency virus-infected patients. J Exp Med 179, 1361.
42. CLERICI M. & SHEARER G.M. (1993) A TH1 to TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14, 107.
43. LANDMAN D., SARAI A. & SATHE S.S. (1994) Use of pentoxifylline therapy for patients with aids-related wasting: pilot study. Clin Infect Dis 18, 97.
44. DENIS M. & GHADIRIAN E. (1994) Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res Human Retrovir 10, 1619.
45. ZABEL P., ENTZIAN P. & SCHLAAK M. (1995) Pentoxifylline for steroid resistant sarcoidosis. In: Proceedings of the World Association of Sarcoidosis and Other Granulomatous Disorders and British Society for Allergy and Clinical Immunology, p.47.